Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 538 of 5804
-
Could a diet and drug combo replace the knife for severe obesity?
Disease control Recruiting nowWith this trial, the aim is to assess the benefits and harms of a non-surgical intensive weight loss intervention that includes total dietary replacements, behavioural support and weight-loss medication compared with bariatric surgery for people with severe and complex obesity. T…
Phase: NA • Sponsor: Carsten Dirksen • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could a single friendly gut bacterium prevent recurrent c. diff?
Prevention Recruiting nowClostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year. This infection is characterized by a high risk of recurrence after cure, ranging from almost 20% after a first episode to over…
Phase: PHASE1, PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Mind over movement: Brain-Controlled therapy aims to restore walking after spinal injury
Disease control Recruiting nowThe purpose of this research is to test the effectiveness of a new therapy, called Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS), for improving walking in people with an incomplete spinal cord injury (SCI).
Phase: NA • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 26, 2026 16:39 UTC
-
New drug combo aims to shrink HER2-Positive tumors
Disease control Recruiting nowThis phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New counseling approach aims to curb youth suicide risk
Symptom relief Recruiting nowThe goal of this RCT study is to test the efficacy of a stratified stepped-care (SSC) model in reducing suicidal thoughts and behaviors (STB) in children and adolescents. The main questions it aims to answer are: 1. Does the SSC model effectively reduce STB and mental health sym…
Phase: NA • Sponsor: Shira Barzilay • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New trial aims to boost colon cancer treatment by giving chemo before surgery
Disease control Recruiting nowThe aim of this study is to determine whether chemotherapy prior to tumor removal (neoadjuvant chemotherapy), in patients undergoing treatment for colon cancer in occlusion (CCO), would improve the rate of patients able to benefit from "optimal" treatment, i.e. complete treatment…
Phase: PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can your apple watch spot hidden heart disease? mayo clinic study says AI might help.
Diagnosis OngoingThe purpose of this study is to evaluate the AI-ECG algorithm for HCM in detecting HCM and in differentiating it from athlete's using not only the standard 12-lead ECG, but also ECGs obtained with the Apple Watch and Alivecor KardiaMobile devices.
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
Massive trial aims to slash infection risk in hip and knee replacements
Prevention Recruiting nowOsteoarthritis (OA) is the most common cause of disability in older adults worldwide affecting 7% of the global population, or more than 500 million people globally. Total joint replacements (TJR) can help bring relief to those with osteoarthritis when other treatment options are…
Phase: PHASE3 • Sponsor: Hamilton Health Sciences Corporation • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
New lung fibrosis pill tested for Long-Term safety in 1,700 patients
Disease control Recruiting nowThis study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out h…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can counseling keep homeless youth off opioids?
Prevention Recruiting nowHomelessness severely affects health and well-being and is particularly negative for youth. Between 70-95% of youth experiencing homelessness (YEH) report problem substance use and 66-89% have a mental health disorder. Youth appear to be at greater risk for living on the streets …
Phase: NA • Sponsor: Ohio State University • Aim: Prevention
Last updated Jun 27, 2026 07:51 UTC
-
Two brain zaps may lift the fog of Schizophrenia's negative symptoms
Symptom relief ENROLLING_BY_INVITATIONDysfunction of the dorsolateral prefrontal cortex (DLPFC) is central to the persistence of negative symptoms in schizophrenia. Both HD-tDCS and iTBS targeting the left DLPFC have shown therapeutic benefit. This trial will test the hypothesis that combining HD-tDCS with iTBS yield…
Phase: NA • Sponsor: Tri-Service General Hospital (TSGH) • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Custom immune cells take on multiple cancers in early trial
Disease control OngoingTScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) m…
Phase: PHASE1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Promising pill may halt vitiligo and bring back pigment
Disease control OngoingVitiligo affects approximately 1 to 2% of the global population and significantly impacts people's quality of life. Achieving the best treatment outcomes for vitiligo involves addressing the autoimmune inflammatory response to stop the depigmentation process and promoting the dif…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to tackle rare blood cancer
Disease control Recruiting nowThe main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.
Phase: PHASE1, PHASE2 • Sponsor: Alvaro Alencar, MD • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New transplant method aims to cut dangerous side effects in blood cancer patients
Disease control Recruiting nowThis study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk m…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New RNA shot directly into tumors could boost immune attack
Disease control Recruiting nowPhase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembroli…
Phase: PHASE1, PHASE2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New pill shows promise in slowing advanced breast cancer
Disease control Recruiting nowTo evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could fewer doses of this prostate cancer drug be just as good?
Disease control Recruiting nowThis phase II trial studies how to improve the usage of Lu 177 vipivotide tetraxetan (177Lu-prostate-specific membrane antigen \[PSMA\]-617) for treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site), to other places…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 26, 2026 15:59 UTC
-
Could a common antibiotic beat stubborn joint infections?
Disease control Recruiting nowCutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI). After shoulder prothesis, C. acnes mainly affects hip prosthesis. One recent work from the Lyon (France) bone and joint infections reference center with data focusing mainly on hip and kn…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental cocktail targets deadly brain lymphoma
Disease control Recruiting nowSecondary involvement of the central nervous system (CNS), such as CNS relapse after treatment or progression during treatment, is a rare but deadly occurrence in patients with B-cell non-Hodgkin lymphoma (NHL), particularly in cases of diffuse large B-cell lymphoma (DLBCL) and t…
Phase: PHASE1, PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC